In the evolving landscape of central nervous system (CNS) oncology, the integration of advanced diagnostic technologies with precision therapeutic innovation is reshaping how clinicians detect, monitor, and manage complex CNS cancers. At CNSide Diagnostics, we are proud to support this transformation by providing actionable, CSF-based insights that help clinicians make more informed decisions for patients with leptomeningeal metastases (LM).

This integrated approach was highlighted in a recent episode of the Progress, Potential, and Possibilities podcast, where Plus Therapeutics’ President & CEO, Marc Hedrick, MD, discussed the company’s strategy, scientific focus, and vision for the future of CNS oncology.

Why CNSide® Matters

The CNSide® CSF Assay Platform delivers detailed, clinically actionable information.

These insights will aim to help clinicians:

• Measure disease burden more sensitively and objectively
• Track response to therapy over time
• Understand molecular drivers that may influence treatment decisions
• Support earlier and more accurate detection of CNS tumor spread

As the need for reliable CNS cancer diagnostics continues to grow, CNSide remains committed to empowering clinicians with high-quality data that strengthens both patient monitoring and therapeutic development.

Learn more about CNSide Diagnostics: https://cnside-dx.com

Watch the Full Podcast Episode

For a deeper look into the strategy, science, and opportunity ahead for Plus Therapeutics and CNSide Diagnostics, watch the full interview here:
https://lnkd.in/gUxrT_Us